{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:06:41Z","timestamp":1791058001201,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.leukres.2011.10.011","type":"journal-article","created":{"date-parts":[[2011,10,31]],"date-time":"2011-10-31T20:09:17Z","timestamp":1320091757000},"page":"438-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia"],"prefix":"10.1016","volume":"36","author":[{"given":"Peter C.","family":"Trask","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.10.011_bib0005","series-title":"Cancer facts and figures 2010","author":"American Cancer Society","year":"2010"},{"issue":"Suppl. 5","key":"10.1016\/j.leukres.2011.10.011_bib0010","doi-asserted-by":"crossref","first-page":"v165","DOI":"10.1093\/annonc\/mdq201","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Baccarani","year":"2010","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.leukres.2011.10.011_bib0015","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.leukres.2011.10.011_bib0020","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.10.011_bib0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2011.10.011_bib0030","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","article-title":"Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials \u2013 a systematic review to evaluate the added value in supporting clinical decision making","volume":"44","author":"Efficace","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2011.10.011_bib0035","article-title":"Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes","author":"Efficace","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.leukres.2011.10.011_bib0040","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.10.011_bib0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0163278705275341","article-title":"General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G)","volume":"28","author":"Brucker","year":"2005","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.leukres.2011.10.011_bib0050","unstructured":"Cella D, Webster K, Beaumont J, Du H, Lai J-S, Rosen S, Tallman M, Yount S. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire, submitted for publication."},{"key":"10.1016\/j.leukres.2011.10.011_bib0055","series-title":"The manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Center on outcomes, research and education","author":"Cella","year":"1997"},{"issue":"3","key":"10.1016\/j.leukres.2011.10.011_bib0060","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.leukres.2011.10.011_bib0065","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2011.10.011_bib0070","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.leukres.2011.10.011_bib0075","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.10.011_bib0080","series-title":"Paper Presented at: 15th Congress of the European Hematology Association","article-title":"Safety and efficacy of second-line bosutinib (SKI-606) in imatinib-resistant or -intolerant chronic phase (CP) chronic myeloid leukemia (CML)","author":"Br\u00fcmmendorf","year":"2010"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100508X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100508X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:57:36Z","timestamp":1758934656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261100508X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S014521261100508X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.10.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2011.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}